Background {#Sec1}
==========

Commonly seen urologic cancers such as prostate cancer, renal cancer, and bladder cancer are leading causes of cancer-related morbidity and mortality globally (Siegel et al. [@CR25]). Despite rapid advances in early diagnosis and surgical treatment over the past few decades, the numbers of new urologic cancer cases and associated deaths are continue to increase, making it becomes one of the major threats to public health worldwide (Ferlay et al. [@CR12]).

To date, the exact cause of urologic cancer remains unclear. Certain environmental factors like smoking habit, heavy alcohol intake, high caloric diet and chemical dyes have been identified as potential etiological factors for urologic cancer. However, the fact that only a small portion of individuals exposed to these carcinogenic agents ultimately develop urologic cancer suggests that genetic susceptibility factors may play a crucial part in its pathogenesis (Jiang et al. [@CR15]).

Interleukin-10 (IL-10), encoded by the *IL*-*10* gene located on chromosome 1q31--32, is a potent regulator of anti-tumor immune responses (Eskdale et al. [@CR10]; Mocellin et al. [@CR22]). As a result, certain polymorphisms located in the promoter region of *IL*-*10* gene (−592C\>A, −819C\>T and −1082A\>G), which regulate the expression level of IL-10 protein (Turner et al. [@CR28]; Kingo et al. [@CR17]), were thought to be implicated in the pathogenesis of various kinds of cancers. Recently, many genetic association studies have been carried out to investigate the potential correlations between *IL*-*10* promoter region polymorphisms and urologic cancer risk. However, results of these studies were controversial and the statistical power of individual studies was insufficient. Therefore, we conducted the present meta-analysis to better assess the potential associations of *IL*-*10* genetic polymorphisms with the risk of urologic cancer.

Methods {#Sec2}
=======

Literature searching strategy {#Sec3}
-----------------------------

To retrieve all relevant articles, a systematic literature search of PubMed, Medline, Embase, Scopus and China National Knowledge Infrastructure (CNKI) was performed using the following keywords: "Interleukin-10", "IL-10", "Interleukin 10", "IL 10", "polymorphism", "variant", "genotype", "allele", "prostate", "renal", "bladder", "urinary", "urologic", "cancer", "tumor", "carcinoma", "neoplasm" and "malignancy". The initial search was conducted in September 2015 and the latest update was performed in May 2016. In addition, the reference lists of all retrieved articles were reviewed manually for further identification of potentially relevant articles.

Inclusion criteria {#Sec4}
------------------

The inclusion criteria for the present study were set prior to the literature search. Eligible studies met all the following conditions: (1) case--control study of unrelated urologic cancer patients and control subjects; (2) evaluation of the associations between *IL*-*10* polymorphisms (−592C\>A, −819C\>T and −1082A\>G) and the risk of urologic cancer; (3) presentation of sufficient data to calculate the odds ratios (ORs) and corresponding 95% confidence intervals (CIs); (4) full text in English or Chinese available. If the report was duplicated or identical patients were enrolled in two studies, only the most recent and complete article was included. Abstracts, family-based association studies, case reports, case series, reviews, editorials, expert opinions and conference presentations were intentionally excluded.

Data extraction and quality assessment {#Sec5}
--------------------------------------

From each included studies, the following data were extracted: references, country of origin, ethnicity of study population, the number of cases and controls, types of urologic cancer, allelic and genotypic frequencies of *IL*-*10* polymorphisms in urologic cancer patients and control subjects, and whether the distributions of *IL*-*10* polymorphisms in the control group were in accordance with Hardy--Weinberg equilibrium (HWE). The Newcastle-ottawa quality assessment scale (NOS), a classical rating tool which evaluates the credibility of observational studies from three perspectives: selection, comparability and exposure, was used to assess the reliability of all case--control studies included (Zhang et al. [@CR35]). This rating system has a score range of 0--9, and studies with a score of more than 7 were assumed to be of high quality. Two reviewers (Shi and Xie) conducted the data extraction and quality assessment independently. When necessary, the reviewers wrote to the corresponding authors for extra information or raw data. Any discrepancies between two reviewers were resolved by discussion until reaching a consensus. The final results were reviewed by a senior reviewer (Li).

Statistical analysis {#Sec6}
--------------------

All data analyses were performed using Review Manager Version 5.3.3 (The Cochrane Collaboration, Software Update, Oxford, United Kingdom). HWE was explored with the Chi square test. ORs and 95% CIs were employed to evaluate potential associations between *IL*-*10* polymorphisms and the risk of urologic cancer. Heterogeneity between studies was assessed by using the Q test and I^2^ statistic. If probability value (*P* value) of Q test was less than 0.1 or I^2^ was greater than 50%, the random-effect model (REM) would be adopted for analyses due to the existence of significant between-study heterogeneity. Otherwise, the fixed-effect model (FEM) would be applied for analyses. Subgroup analyses were performed based on types of cancer and ethnicity of study population. Sensitivity analyses were carried out by omitting one individual study each time. Publication bias was further evaluated with funnel plots. And a *P* value of 0.05 or less was considered to be statistically significant for all analyses.

Results {#Sec7}
=======

Included studies {#Sec8}
----------------

The literature search yielded 462 results. After exclusion of irrelevant or duplicate articles by reading titles and abstracts, 39 articles were selected for further evaluation. Among these, a total of 22 case--control studies including 8572 urologic cancer patients and 9843 control subjects met our inclusion criteria (see Fig. [1](#Fig1){ref-type="fig"}), 14/22 were about the *IL*-*10* −592C\>A polymorphism, 13/22 were about the *IL*-*10* −819C\>T polymorphism, and 20/22 were about the *IL*-*10* −1082A\>G polymorphism. All included studies were published between 2002 and 2016. Of these, there were 16 studies of prostate cancer, 4 studies of renal cancer, and 2 studies of bladder cancer. All articles were published in English except for two in Chinese. Characteristics of studies analyzing *IL*-*10* −592C\>A polymorphism were summarized in Table [1](#Tab1){ref-type="table"}, characteristics of studies examining *IL*-*10* −819C\>T polymorphism were summarized in Table [2](#Tab2){ref-type="table"}, and characteristics of studies investigating *IL*-*10* −1082A\>G polymorphism were summarized in Table [3](#Tab3){ref-type="table"}. Fig. 1Flowchart of study selection for the present study Table 1The characteristics of the included studies for *IL*-*10* −592 C/A polymorphism and urologic cancer riskReferencesCountryEthnicityCaseControl*P* value HWENOS scorenGenotypes CC/CA/AAAlleles C/A (%)nGenotypes CC/CA/AAAlleles C/A (%)*Prostate cancer*Dluzniewski et al. ([@CR6])USAMixed442236/171/3572.7/27.3442253/168/2176.2/23.80.3007Dwivedi et al. ([@CR7], [@CR8])IndiaAsian291110/125/5659.3/40.729198/138/5557.4/42.60.6048Eder et al. ([@CR9])AustriaCaucasian547293/219/3573.6/26.4545296/216/3374.1/25.90.4378Faupel-Badger et al. ([@CR11])USACaucasian510284/188/3974.1/25.9386243/124/1979.0/21.00.5397Liu et al. ([@CR19])ChinaAsian26234/108/12033.6/66.427028/110/13230.7/69.30.4778VanCleave et al. ([@CR30])USAAfrican18972/87/3061.1/38.9651251/288/11260.7/39.30.0638Wang et al. ([@CR31])USACaucasian255150/95/1077.5/22.5255162/84/980.0/20.00.6397Winchester et al. ([@CR32])USAMixed826495/280/5176.9/23.1827511/269/4778.1/21.90.1468Xu et al. ([@CR33])SwedenCaucasian1383NA74.0/26.0780NA75.0/25.0NA8Zabaleta et al. ([@CR34])USAMixed546314/191/4175.0/25.0529258/228/4370.3/29.70.4548*Renal cancer*Basturk et al. ([@CR2])TurkeyCaucasian2913/14/268.9/31.15024/19/767.0/33.00.3207Cozar et al. ([@CR5])SpainCaucasian12781/37/978.3/21.717598/63/1474.0/26.00.3948Chang et al. ([@CR3])TaiwanAsian924/27/6119.0/81.058024/185/37120.1/79.90.8778*Bladder cancer*Chen et al. ([@CR4])ChinaAsian40042/140/21828.0/72.040064/168/16827.0/73.0*0.047*8*P* value of HWE test \<0.05, which reached the statistically significant level are indicated in italics*HWE* Hardy--Weinberg equilibrium, *NOS* Newcastle--Ottawa Quality Assessment Scale, *NA* not available Table 2The characteristics of the included studies for *IL*-*10* −819 C/T polymorphism and urologic cancer riskReferencesCountryEthnicityCaseControl*P* value HWENOS scorenGenotypes CC/CT/TTAlleles C/T (%)nGenotypes CC/CT/TTAlleles C/T (%)*Prostate cancer*Dwivedi et al. ([@CR7], [@CR8])IndiaAsian29168/131/9245.9/54.129160/151/8046.6/53.40.4668Faupel-Badger et al. ([@CR11])USACaucasian507283/184/4074.0/26.0384244/122/1879.4/20.60.5857Kesarwani et al. ([@CR16])IndiaAsian15952/68/3954.1/45.925965/125/6949.2/50.80.5798Liu et al. ([@CR19])ChinaAsian26234/108/12033.6/66.427028/110/13230.7/69.30.4778Michaud et al. ([@CR21])USAMixed1246716/447/8375.4/24.61762964/659/13973.4/26.60.0788VanCleave et al. ([@CR30])USAAfrican19176/85/3062.0/38.0635246/278/11160.6/39.4*0.037*8Winchester et al. ([@CR32])USAMixed611372/206/3377.7/22.3659408/217/3478.4/21.60.4648Zabaleta et al. ([@CR34])USAMixed526308/180/3875.7/24.3494249/204/4171.1/28.90.9318*Renal cancer*Basturk et al. ([@CR2])TurkeyCaucasian2913/14/269.0/31.05024/19/767.0/33.00.3207Cozar et al. ([@CR5])SpainCaucasian12781/37/978.3/21.717598/63/1474.0/26.00.3948Chang et al. ([@CR3])TaiwanAsian924/26/6218.5/81.558061/209/31028.5/71.5*0.005*8*Bladder cancer*Ahirwar et al. ([@CR1])IndiaAsian21446/103/6545.6/54.4385115/165/10551.3/48.7*0.005*8Chen et al. ([@CR4])ChinaAsian40042/140/21828.0/72.040064/168/16837.0/63.0*0.047*8*P* value of HWE test \<0.05, which reached the statistically significant level are indicated in italics*HWE* Hardy--Weinberg equilibrium, *NOS* Newcastle--Ottawa Quality Assessment Scale, *NA* not available Table 3The characteristics of the included studies for *IL*-*10* −1082 A/G polymorphism and urologic cancer riskReferencesCountryEthnicityCaseControl*P* value HWENOS scorenGenotypes AA/AG/GGAlleles A/G (%)nGenotypes AA/AG/GGAlleles A/G (%)*Prostate cancer*Dluzniewski et al. ([@CR6])USAMixed458146/212/10055.0/45.0458112/242/10450.9/49.10.2227Faupel-Badger et al. ([@CR11])USACaucasian509173/251/8558.6/41.4382115/194/7355.5/44.50.5827Ianni et al. ([@CR14])ItalyCaucasian17179/74/1845.2/54.89625/43/2848.4/51.60.3127Kesarwani et al. ([@CR16])IndiaAsian15969/78/1267.9/32.1259111/103/4562.7/37.3*0.016*8Liu et al. ([@CR19])ChinaAsian262222/36/491.6/8.4270240/27/393.9/6.1*0.035*8McCarron et al. ([@CR20])UKCaucasian24778/113/5654.5/45.522346/120/5747.5/52.50.2397Michaud et al. ([@CR21])USAMixed1245356/599/29052.7/47.31763523/857/38354.0/46.00.3648Niu ([@CR23])ChinaAsian9824/56/1853.1/46.98842/44/272.7/27.3*0.015*7Omrani et al. ([@CR24])IranCaucasian415/31/550.0/50.010316/77/1052.9/47.1*\<0.0001*7VanCleave et al. ([@CR30])USAAfrican19222/95/7536.3/63.766092/280/28835.2/64.80.0748Wang et al. ([@CR31])USACaucasian25556/130/6947.6/52.425783/117/5755.1/44.90.1997Winchester et al. ([@CR32])USAMixed832206/434/19263.0/37.0836204/429/20350.1/49.90.4478Xu et al. ([@CR33])SwedenCaucasian1383NA53.0/47.0780NA51.0/49.0NA8Zabaleta et al. ([@CR34])USAMixed541131/277/13349.8/50.2523144/280/9954.3/45.70.0728*Renal cancer*Basturk et al. ([@CR2])TurkeyCaucasian2917/9/374.1/25.95032/13/577.0/23.00.0607Cozar et al. ([@CR5])SpainCaucasian12642/62/2257.9/42.117558/87/3058.0/42.00.7878Havranek et al. ([@CR13])UKMixed14765/56/2663.3/36.714945/69/3553.4/46.60.3957Chang et al. ([@CR3])TaiwanAsian9271/16/585.9/14.1580444/107/2985.8/14.2*\<0.0001*8*Bladder cancer*Ahirwar et al. ([@CR1])IndiaAsian21484/112/1865.4/34.6385143/181/6160.6/39.40.7688Chen et al. ([@CR4])ChinaAsian400374/25/196.6/3.4400350/48/293.5/6.50.7998*P* value of HWE test \<0.05, which reached the statistically significant level are indicated in italics*HWE* Hardy--Weinberg equilibrium, *NOS* Newcastle--Ottawa Quality Assessment Scale, *NA* not available

Risk of bias in included studies {#Sec9}
--------------------------------

As shown in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}, the average NOS score of included studies was 7.59 (range from 7 to 8), suggesting that all enrolled articles were of relatively high quality. The improper selection of controls and mismatching baseline characteristics of urologic cancer cases and control subjects (age and/or ethnicity) were the major sources of biases.

*IL*-*10* −592C\>A polymorphism and urologic cancer risk {#Sec10}
--------------------------------------------------------

For *IL*-*10* −592C\>A polymorphism, a total of 14 studies including 5899 urologic cancer patients and 6181 control subjects were investigated (Dluzniewski et al. [@CR6]; Dwivedi et al. [@CR7], [@CR8]; Eder et al. [@CR9]; Faupel-Badger et al. [@CR11]; Liu et al. [@CR19]; VanCleave et al. [@CR30]; Wang et al. [@CR31]; Winchester et al. [@CR32]; Xu et al. [@CR33]; Zabaleta et al. [@CR34]; Basturk et al. [@CR2]; Cozar et al. [@CR5]; Chang et al. [@CR3]; Chen et al. [@CR4]). HWE test for the control group of each included studies demonstrated that only 1 study deviated from HWE (see Table [1](#Tab1){ref-type="table"}). In order to explore the association between *IL*-*10* −592C\>A polymorphism and urologic cancer risk, we compared distribution of genotypes and alleles in every genetic model. For CC versus AA, CA versus AA, CA versus CC+AA, and AA versus CC+CA, between-study heterogeneity was mild, and analyses were performed with FEMs. For CC versus CA, CC versus CA+AA, and C versus A, REMs were selected due to severe between-study heterogeneity. A significant association with urologic cancer was found for *IL*-*10* −592C\>A polymorphism in CA versus AA (*P* = 0.04, OR 0.87, 95% CI 0.76--0.99) and AA versus CC+CA (*P* = 0.03, OR 1.15, 95% CI 1.02--1.31) (see Figs. [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}).Fig. 2Forest plots on association between *IL*-*10* −592C\>A polymorphism and urologic cancer risk. **a** Forest plot of CC versus CA for *IL*-*10* −592C\>A polymorphism and urologic cancer risk is shown. **b** Forest plot of CC versus AA for *IL*-*10* −592C\>A polymorphism and urologic cancer risk is shown. **c** Forest plot of CA versus AA for *IL*-*10* −592C\>A polymorphism and urologic cancer risk is shown. **d** Forest plot of CC versus CA+AA for *IL*-*10* −592C\>A polymorphism and urologic cancer risk is shown Fig. 3Forest plots on association between *IL*-*10* −592C\>A polymorphism and urologic cancer risk. **a** Forest plot of CA versus CC+AA for *IL*-*10* −592C\>A polymorphism and urologic cancer risk is shown. **b** Forest plot of AA versus CC+CA for *IL*-*10* −592C\>A polymorphism and urologic cancer risk is shown. **c** Forest plot of C versus A for *IL*-*10* −592C\>A polymorphism and urologic cancer risk is shown

*IL*-*10* −819C\>T polymorphism and urologic cancer risk {#Sec11}
--------------------------------------------------------

A total of 13 studies with 4655 cancer cases and 6344 healthy controls were enrolled to evaluate the association between *IL*-*10* −819C\>T polymorphism and urologic cancer risk (Dwivedi et al. [@CR7], [@CR8]; Faupel-Badger et al. [@CR11]; Liu et al. [@CR19]; VanCleave et al. [@CR30]; Winchester et al. [@CR32]; Zabaleta et al. [@CR34]; Basturk et al. [@CR2]; Cozar et al. [@CR5]; Chang et al. [@CR3]; Chen et al. [@CR4]; Kesarwani et al. [@CR16]; Michaud et al. [@CR21]; Ahirwar et al. [@CR1]). HWE test for the control group of eligible studies revealed that 4 studies violated HWE (see Table [2](#Tab2){ref-type="table"}). All genetic models were tested to detect any differences in genotypic and allelic frequencies of cases and controls. For CT versus TT, there was only trivial between-study heterogeneity, and FEM was employed for analysis. For CC versus CT, CC versus TT, CC versus CT+TT, CT versus CC+TT, TT versus CC+CT, and C versus T, between-study heterogeneity was obvious, and REMs were adopted for analyses. No significant association with urologic cancer was found for *IL*-*10* −819C\>T polymorphism in any genetic models (see Figs. [4](#Fig4){ref-type="fig"}, [5](#Fig5){ref-type="fig"}).Fig. 4Forest plots on association between *IL*-*10* −819C\>T polymorphism and urologic cancer risk. **a** Forest plot of CC versus CT for *IL*-*10* −819C\>T polymorphism and urologic cancer risk is shown. **b** Forest plot of CC versus TT for *IL*-*10* −819C\>T polymorphism and urologic cancer risk is shown. **c** Forest plot of CT versus TT for *IL*-*10* −819C\>T polymorphism and urologic cancer risk is shown. **d** Forest plot of CC versus CT+TT for *IL*-*10* −819C\>T polymorphism and urologic cancer risk is shown Fig. 5Forest plots on association between *IL*-*10* −819C\>T polymorphism and urologic cancer risk. **a**. Forest plot of CT versus CC+TT for *IL*-*10* −819C\>T polymorphism and urologic cancer risk is shown. **b** Forest plot of TT versus CC+CT for *IL*-*10* −819C\>T polymorphism and urologic cancer risk is shown. **c** Forest plot of C versus T for *IL*-*10* −819C\>T polymorphism and urologic cancer risk is shown

*IL*-*10* −1082A\>G polymorphism and urologic cancer risk {#Sec12}
---------------------------------------------------------

Of the 20 included studies for *IL*-*10* −1082A\>G polymorphism, there were 7401 urologic cancer patients and 8437 controls (Dluzniewski et al. [@CR6]; Faupel-Badger et al. [@CR11]; Liu et al. [@CR19]; VanCleave et al. [@CR30]; Wang et al. [@CR31]; Winchester et al. [@CR32]; Xu et al. [@CR33]; Zabaleta et al. [@CR34]; Basturk et al. [@CR2]; Cozar et al. [@CR5]; Chang et al. [@CR3]; Chen et al. [@CR4]; Kesarwani et al. [@CR16]; Michaud et al. [@CR21]; Ahirwar et al. [@CR1]; Ianni et al. [@CR14]; McCarron et al. [@CR20]; Niu [@CR23]; Omrani et al. [@CR24]; Havranek et al. [@CR13]). Deviations from HWE were found in 5 studies while the remaining 15 studies were in accordance with HWE (see Table [3](#Tab3){ref-type="table"}). For evaluation of the association between *IL*-*10* −1082A\>G polymorphism and urologic cancer risk, frequencies of genotypes and alleles in cases and control subjects were compared in every genetic model. REMs were used for all analyses on account of striking between-study heterogeneity, and no significant association was detected between *IL*-*10* −1082A\>G polymorphism and urologic cancer risk (see Figs. [6](#Fig6){ref-type="fig"}, [7](#Fig7){ref-type="fig"}).Fig. 6Forest plots on association between *IL*-*10* −1082A\>G polymorphism and urologic cancer risk. **a** Forest plot of AA versus AG for *IL*-*10* −1082A\>G polymorphism and urologic cancer risk is shown. **b** Forest plot of AA versus GG for *IL*-*10* −1082A\>G polymorphism and urologic cancer risk is shown. **c** Forest plot of AG versus GG for *IL*-*10* −1082A\>G polymorphism and urologic cancer risk is shown. **d** Forest plot of AA versus AG+GG for *IL*-*10* −1082A\>G polymorphism and urologic cancer risk is shown Fig. 7Forest plots on association between *IL*-*10* −1082A\>G polymorphism and urologic cancer risk. **a** Forest plot of AG versus AA+GG for *IL*-*10* −1082A\>G polymorphism and urologic cancer risk is shown. **b** Forest plot of GG versus AA+AG for *IL*-*10* −1082A\>G polymorphism and urologic cancer risk is shown. **c** Forest plot of A versus G for *IL*-*10* −1082A\>G polymorphism and urologic cancer risk is shown

Subgroup analysis {#Sec13}
-----------------

For *IL*-*10* polymorphisms (−592C\>A, −819C\>T, −1082A\>G) and urologic cancer risk, subgroup analyses were performed by stratifying available data according to types of cancer and ethnicity of study population. When data were stratified by cancer types, we found that *IL*-*10* −592C\>A polymorphism was significantly associated with bladder cancer risk in CC versus AA (*P* = 0.002, OR 0.51, 95% CI 0.33--0.78), CA versus AA (*P* = 0.004, OR 0.64, 95% CI 0.48--0.87), CC versus CA+AA (*P* = 0.02, OR 0.62, 95% CI 0.41--0.93), CA versus CC+AA (*P* = 0.04, OR 0.74, 95% CI 0.56--0.99), AA versus CC+CA (*P* = 0.0004, OR 1.65, 95% CI 1.25--2.19), and C versus A (*P* = 0.00001, OR 0.66, 95% CI 0.54--0.82). Besides, *IL*-*10* −819C\>T polymorphism was significantly correlated with bladder cancer risk in CC versus CT (*P* = 0.03, OR 0.71, 95% CI 0.52--0.96), CC versus TT (*P* = 0.0005, OR 0.57, 95% CI 0.41--0.78), CC versus CT+TT (*P* = 0.002, OR 0.63, 95% CI 0.47--0.84), and C versus T (*P* \< 0.00001, OR 0.72, 95% CI 0.61--0.84). Additionally, *IL*-*10* −1082A\>G polymorphism was also significantly associated with the risk of bladder cancer in AA versus GG (*P* = 0.02, OR 2.00, 95% CI 1.13--3.55), AG versus GG (*P* = 0.01, OR 2.03, 95% CI 1.16--3.55), and GG versus AA+AG (*P* = 0.009, OR 0.49, 95% CI 0.28--0.84). When data were subsequently stratified by ethnicity, we observed a significant association with urologic cancer risk for *IL*-*10* −819C\>T polymorphism in CT versus TT (*P* = 0.0009, OR 0.81, 95% CI 0.69--0.95). No any other associations were found in subgroup analyses (see Tables [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"}).Table 4Subgroup analyses for *IL*-*10* −592C\>A polymorphism and urologic cancer riskVariables*P* valueOR (95% Cl)*I*-square (%)*P* for the heterogeneity*Cancer type*Prostate cancer (No.^a^: 10) CC versus CA0.991.00 (0.87--1.15)490.05 CC versus AA0.510.94 (0.80--1.12)220.25 CA versus AA0.370.93 (0.79--1.09)00.85 CC versus CA+AA0.850.99 (0.85--1.14)560.02 CA versus CC+AA0.971.00 (0.91--1.09)360.13 AA versus CC+CA0.471.06 (0.91--1.23)00.54 C versus A0.550.97 (0.89--1.07)490.04Renal cancer (No.^a^: 3) CC versus CA0.351.21 (0.80--1.83)00.50 CC versus AA0.471.26 (0.67--2.36)00.83 CA versus AA0.940.99 (0.65--1.49)00.50 CC versus CA+AA0.301.23 (0.83--1.82)00.66 CA versus CC+AA0.400.87 (0.63--1.20)00.39 AA versus CC+CA0.981.00 (0.67--1.47)00.56 C versus A0.481.10 (0.85--1.41)00.55Bladder cancer (No.^a^: 1) CC versus CA0.300.79 (0.50--1.23)NANA CC versus AA*0.0020.51 (0.33--0.78)*NANA CA versus AA*0.0040.64 (0.48--0.87)*NANA CC versus CA+AA*0.020.62 (0.41--0.93)*NANA CA versus CC+AA*0.040.74 (0.56--0.99)*NANA AA versus CC+CA*0.00041.65 (1.25--2.19)*NANA C versus A*0.000010.66 (0.54--0.82)*NANA*Ethnicity*Asian (No.^a^: 4) CC versus CA0.571.07 (0.84--1.37)00.44 CC versus AA0.700.91 (0.55--1.50)680.03 CA versus AA0.050.82 (0.68--1.00)400.17 CC versus CA+AA0.930.98 (0.66--1.46)580.07 CA versus CC+AA0.060.85 (0.71--1.01)00.58 AA versus CC+CA0.381.15 (0.84--1.58)660.03 C versus A0.610.93 (0.70--1.23)780.003Caucasian (No.^a^: 7) CC versus CA0.890.99 (0.86--1.13)520.06 CC versus AA0.310.87 (0.66--1.14)00.58 CA versus AA0.370.88 (0.66--1.16)00.75 CC versus CA+AA0.840.98 (0.80--1.20)530.06 CA versus CC+AA1.001.00 (0.82--1.22)490.08 AA versus CC+CA0.301.15 (0.88--1.51)00.70 C versus A0.310.96 (0.88--1.04)350.16The difference in cases and controls regarding the distributions of investigated genetic polymorphisms in certain genetic model reached the statistically significant level, which is also less than 0.05 are indicated in italics*OR* odds ratio, *CI* confidence interval, *NA* not applicable^a^The number of articles Table 5Subgroup analyses for *IL*-*10* −819C\>T polymorphism and urologic cancer riskVariables*P* valueOR (95% Cl)I-square (%)*P* for the heterogeneity*Cancer type*Prostate cancer (No.^a^: 8) CC versus CT0.221.10 (0.95--1.27)460.07 CC versus TT0.181.11 (0.95--1.30)270.22 CT versus TT0.790.98 (0.85--1.14)00.68 CC versus CT+TT0.271.09 (0.94--1.27)560.03 CT versus CC+TT0.160.94 (0.86--1.03)320.17 TT versus CC+CT0.630.97 (0.84--1.11)90.36 C versus T0.441.05 (0.93--1.17)580.02Renal cancer (No.^a^: 3) CC versus CT0.751.07 (0.71--1.59)400.19 CC versus TT0.770.85 (0.30--2.46)600.08 CT versus TT0.150.74 (0.49--1.11)260.26 CC versus CT+TT0.710.87 (0.42--1.80)610.08 CT versus CC+TT0.130.78 (0.57--1.08)120.32 TT versus CC+CT0.081.42 (0.96--2.09)500.13 C versus T0.740.91 (0.52--1.60)770.01Bladder cancer (No.^a^: 2) CC versus CT*0.030.71 (0.52--0.96)*00.51 CC versus TT*0.00050.57 (0.41--0.78)*00.45 CT versus TT0.290.79 (0.51--1.23)680.08 CC versus CT+TT*0.0020.63 (0.47--0.84)*00.88 CT versus CC+TT0.850.95 (0.58--1.57)800.02 TT versus CC+CT0.05*1.42 (1.01--2.00)*550.14 C versus T **\<0.00001***0.72 (0.61--0.84)*210.26*Ethnicity*Asian (No.^a^: 6) CC versus CT0.910.98 (0.72--1.35)560.04 CC versus TT0.300.81 (0.55--1.21)690.006 CT versus TT*0.0090.81 (0.69--0.95)*340.18 CC versus CT+TT0.540.89 (0.62--1.28)700.005 CT versus CC+TT0.050.87 (0.75--1.00)360.17 TT versus CC+CT0.091.23 (0.97--1.56)600.03 C versus T0.210.87 (0.70--1.08)770.0005Caucasian (No.^a^: 4) CC versus CT0.811.04 (0.74--1.48)640.04 CC versus TT0.250.81 (0.57--1.16)330.21 CT versus TT0.220.79 (0.55--1.15)00.53 CC versus CT+TT0.891.03 (0.72--1.46)680.02 CT versus CC+TT0.770.95 (0.69--1.31)580.07 TT versus CC+CT0.331.22 (0.82--1.80)130.33 C versus T0.971.01 (0.75--1.34)680.02The difference in cases and controls regarding the distributions of investigated genetic polymorphisms in certain genetic model reached the statistically significant level, which is also less than 0.05 are indicated in italics*OR* odds ratio, *CI* confidence interval^a^The number of articles Table 6Subgroup analyses for *IL*-*10* −1082A\>G polymorphism and urologic cancer riskVariables*P* valueOR (95% Cl)*I*-square (%)*P* for the heterogeneity*Cancer type*Prostate cancer (No.^a^: 14) AA versus AG0.840.98 (0.82--1.17)650.0007 AA versus GG0.661.07 (0.80--1.42)79\<0.0001 AG versus GG0.611.05 (0.87--1.27)610.002 AA versus AG+GG0.900.99 (0.81--1.20)75\<0.0001 AG versus AA+GG0.991.00 (0.93--1.08)360.10 GG versus AA+AG0.530.94 (0.76--1.15)71\<0.0001 A versus G0.781.02 (0.90--1.15)79\<0.0001Renal cancer (No.^a^: 4) AA versus AG0.211.21 (0.90--1.62)140.32 AA versus GG0.231.28 (0.85--1.92)00.41 AG versus GG0.941.02 (0.68--1.51)00.98 AA versus AG+GG0.171.21 (0.92--1.59)340.21 AG versus AA+GG0.380.88 (0.67--1.16)00.67 GG versus AA+AG0.490.88 (0.61--1.27)00.78 A versus G0.171.15 (0.94--1.40)290.24Bladder cancer (No.^a^: 2) AA versus AG0.421.37 (0.64--2.90)830.01 AA versus GG*0.022.00 (1.13--3.55)*00.96 AG versus GG*0.012.03 (1.16--3.55)*00.59 AA versus AG+GG0.231.46 (0.79--2.70)760.04 AG versus AA+GG0.620.79 (0.32--1.97)890.003 GG versus AA+AG*0.0090.49 (0.28--0.84)*00.99 A versus G0.091.49 (0.94--2.38)680.08*Ethnicity*Asian (No.^a^: 6) AA versus AG0.700.93 (0.65--1.33)680.007 AA versus GG0.900.95 (0.39--2.30)760.0009 AG versus GG0.741.14 (0.53--2.48)670.01 AA versus AG+GG0.760.94 (0.64--1.39)760.0008 AG versus AA+GG0.601.09 (0.79--1.51)640.02 GG versus AA+AG0.890.94 (0.42--2.12)730.003 A versus G0.991.00 (0.69--1.44)83\<0.0001Caucasian (No.^a^: 9) AA versus AG0.621.07 (0.81--1.41)590.02 AA versus GG0.541.15 (0.73--1.82)78\<0.0001 AG versus GG0.971.00 (0.84--1.19)310.18 AA versus AG+GG0.591.09 (0.79--1.50)730.0004 AG versus AA+GG0.490.95 (0.83--1.09)00.67 GG versus AA+AG0.400.89 (0.67--1.17)570.02 A versus G0.551.07 (0.85--1.34)79\<0.0001The difference in cases and controls regarding the distributions of investigated genetic polymorphisms in certain genetic model reached the statistically significant level, which is also less than 0.05 are indicated in italics*OR* odds ratio, *CI* confidence interval^a^The number of articles

Sensitivity analysis {#Sec14}
--------------------

Sensitivity analyses were carried out through removing one individual study each time. For *IL*-*10* −519C\>A polymorphism, when the study performed by Dluzniewski et al. ([@CR6]), Faupel-Badger et al. ([@CR11]) or Chen et al. ([@CR4]) was excluded, the significant association with urologic cancer was no longer observed in CA versus AA, and AA versus CC+CA. For *IL*-*10* −819C\>T polymorphism, when the study of Liu et al. ([@CR19]) or Michaud et al. ([@CR21]) was removed, the null association with urologic cancer in CT versus TT was altered. For *IL*-*10* −1082A\>G polymorphism, however, removing any study did not impact the overall results.

Publication bias {#Sec15}
----------------

Potential publication bias was evaluated with funnel plots. Visual inspection of funnel plots revealed no apparent asymmetry for *IL*-*10* −592C\>A, −819C\>T, and −1082A\>G polymorphisms. And these results indicated that significant publication bias was unlikely.

Discussion {#Sec16}
==========

Urologic cancer is a major public health problem. According to a recent survey, prostate cancer, renal cancer and bladder cancer altogether accounted for 13.3% (1879,000/14090,000) new cancer cases and 7.5% (616,000/8201,000) cancer-related deaths worldwide in 2012, making the urologic cancer ranked as the second most common group of malignancies in terms of morbidity, and the third most common group of malignancies in terms of mortality (Ferlay et al. [@CR12]).

To date, the etiologies of urologic cancer are still largely unknown in spite of extensive studies. However, it has become evident recently that multiple immunomodulatory cytokines are implicated in the process of tumor genesis (Kurzrock [@CR18]; Smyth et al. [@CR26]). Among these cytokines, IL-10 is a multifunctional immunological regulator mainly produced by B cells, T cells and activated monocytes/marcophages. As an important modulator of immune responses, IL-10 can be both tumor-promoting and tumor-inhibiting since it has both immunosuppressive and anti-angiogenic functions (Mocellin et al. [@CR22]). On the one hand, the immunosuppressive property of IL-10 may suppress anti-tumor immune responses and promote tumor development. On the other hand, the anti-angiogenic property of IL-10 may inhibit microvasculature formation and tumor growth. Previous studies have found that serum level of IL-10 was significantly elevated in urologic cancer, and it was closely correlated with tumor progression and metastasis (Stearns et al. [@CR27]; Uwatoko et al. [@CR29]; Dwivedi et al. [@CR7], [@CR8]), which suggested that IL-10 may play a vital role in the development of urologic cancer.

*IL*-*10* gene is located on chromosome 1q31--32. Common promoter region polymorphisms of *IL*-*10* gene, −592C\>A (rs1800872), −819C\>T (rs1800871) and −1082A\>G (rs1800896) were found to influence the production of IL-10 (Turner et al. [@CR28]; Kingo et al. [@CR17]). Consequently, it is biologically plausible that these polymorphisms may be associated with susceptibility to urologic cancer.

Recently, numerous studies have tried to explore the potential associations between *IL*-*10* polymorphisms and the risk of urologic cancer, but the results were contradicted. Thus, we conducted the present meta-analysis to solve the conflict and obtain a more conclusive result. And our overall analyses suggested that *IL*-*10* −592C\>A polymorphism was significantly associated with the risk of urologic cancer in CA versus AA, and AA versus CC+CA. However, we failed to detect any significant associations with urologic cancer for *IL*-*10* −819C\>T and −1082A\>G polymorphisms in overall analyses. Considering the differences of carcinogenic mechanisms for each type of cancer and the importance of ethnic background in genetic investigations, stratified analyses were subsequently performed by categorizing included studies into different subgroups on the basis of types of cancer and ethnicity of study population. When data were stratified by types of cancer, we found that *IL*-*10* −592C\>A, −819C\>T and −1082A\>G polymorphisms were all significantly associated with the risk of bladder cancer in certain genetic models. In addition, the A allele of −592C\>A polymorphism and T allele of −819C\>T polymorphism conferred an increased susceptibility to bladder cancer. When data were stratified by ethnicity of study population, a significant association with urologic cancer risk in Asians was detected for *IL*-*10* −819C\>T polymorphism in CT versus TT. No any other significant associations between *IL*-*10* polymorphisms and urologic cancer risk were observed in subgroup analyses. For the evaluation of the heterogeneity, we found that the between-study heterogeneity remained significant in several subgroup comparisons, suggesting that differences in cancer type and ethnicity could not fully elucidate the observed inconsistent results, and other unmeasured characteristics of study participants may partially attribute to the heterogeneity between studies. Moreover, we noticed a substantial decrease of heterogeneity for *IL*-*10* −592C\>A polymorphism when the study performed by Zabaleta et al. ([@CR34]) was omitted, and that for *IL*-*10* −819C\>T polymorphism when the study conducted by Chen et al. ([@CR4]) was removed or that for *IL*-*10* 1082A\>G polymorphism when the studies of Ianni et al. ([@CR14]) and Niu ([@CR23]) were excluded, which suggested that these studies were the major sources of the observed heterogeneity.

This study is certainly not without limitations. Firstly, the number of studies investigating the associations of certain *IL*-*10* polymorphisms with renal cancer or bladder cancer is still limited, and sample size of several included studies were obviously not sufficient, which precluded us from drawing definite conclusions. Secondly, our results were based on unadjusted estimates since the majority of included studies failed to report baseline characteristics of individuals, such as age, sex, smoking status and eating habits. And lack of analyses adjusted for these potential confounding factors may affect the reliability of our results. Thirdly, although funnel plots revealed no apparent publication bias, we still could not eliminate the possibility of publication bias since only published studies were included. Fourthly, all included studies were published in English or Chinese, therefore, maybe some qualified articles in other languages were missed. Fifthly, genetic associations of *IL*-*10* polymorphisms with urologic cancer may also be influenced by gene--gene and gene-environmental interactions. It is possible that one certain polymorphism may be associated with the risk of urologic cancer, but due to interactions with multiple genes and environmental factors, the association would no longer be observed.

Conclusions {#Sec17}
===========

In conclusion, the current meta-analysis suggests that *IL*-*10* −592C\>A polymorphism may implicate with urologic cancer risk. Besides, promoter region polymorphisms of *IL*-*10* may serve as potential biological markers, especially for bladder cancer. Furthermore, *IL*-*10* −819C\>T polymorphism may contribute to urologic cancer susceptibility in Asians while all the three studied variants of *IL*-*10* did not relate to Caucasian urologic cancer predisposition. However, it should be pointed out that the present results concerning renal cancer and bladder cancer were based on limited number of case--control studies, and further multi-center studies with larger sample size from different populations are warranted to confirm our results. Besides, given that immunomodulating cytokines play a crucial role in regulating anti-tumor immune responses, future investigations are needed to explore the potential roles of other polymorphisms of these cytokine genes in the occurrence and development of urologic cancer.
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